Your browser doesn't support javascript.
loading
NextGen cell-based immunotherapies in cancer and other immune disorders.
Azimi, Camillia S; Tang, Qizhi; Roybal, Kole T; Bluestone, Jeffrey A.
Afiliação
  • Azimi CS; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, Sa
  • Tang Q; UCSF Diabetes Center, University of California, San Francisco, San Francisco, CA, USA; Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
  • Roybal KT; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, Sa
  • Bluestone JA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA; UCSF Diabetes Center, University of California, San Francisco, San Francisco, CA, USA. Electronic address: Jeff.bluesto
Curr Opin Immunol ; 59: 79-87, 2019 08.
Article em En | MEDLINE | ID: mdl-31071513
ABSTRACT
T lymphocyte and other cell therapies have the potential to transform how we treat cancers and other diseases that have few therapeutic options. Here, we review the current progress in engineered T cell therapies and look to the future of what will establish cell therapy as the next pillar of medicine. The tools of synthetic biology along with fundamental knowledge in cell biology and immunology have enabled the development of approaches to engineer cells with enhanced capacity to recognize and treat disease safely and effectively. This along with new modes of engineering cells with CRISPR and strategies to make universal 'off-the-shelf' cell therapies will provide more rapid, flexible, and cheaper translation to the clinic.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T / Imunoterapia Adotiva / Vacinas Anticâncer / Doenças do Sistema Imunitário / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T / Imunoterapia Adotiva / Vacinas Anticâncer / Doenças do Sistema Imunitário / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article